Related Experiment Video
Updated: Feb 28, 2026
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer
Radosław Januchowski1, Karolina Sterzyńska1, Piotr Zawierucha1,2
1Department of Histology and Embryology, Poznań University of Medical Sciences, Poznań, 60-781, Poland.
Purpose:
The present study is to discover a new genes associated with drug resistance development in ovarian cancer.
Methods:
We used microarray analysis to determine alterations in the level of expression of genes in cisplatin- (CisPt), doxorubicin- (Dox), topotecan- (Top), and paclitaxel- (Pac) resistant variants of W1 and A2780 ovarian cancer cell lines. Immunohistochemistry assay was used to determine protein expression in ovarian cancer patients.
Results:
We observed alterations in the expression of 22 genes that were common to all three cell lines that were resistant to the same cytostatic drug. The level of expression of 13 genes was upregulated and that of nine genes was downregulated. In the CisPt-resistant cell line, we observed downregulated expression of ABCC6, BST2, ERAP2 and MCTP1; in the Pac-resistant cell line, we observe upregulated expression of ABCB1, EPHA7 and RUNDC3B and downregulated expression of LIPG, MCTP1, NSBP1, PCDH9, PTPRK and SEMA3A. The expression levels of three genes, ABCB1, ABCB4 and IFI16, were upregulated in the Dox-resistant cell lines. In the Top-resistant cell lines, we observed increased expression levels of ABCG2, HERC5, IFIH1, MYOT, S100A3, SAMD4A, SPP1 and TGFBI and decreased expression levels of MCTP1 and PTPRK. The expression of EPHA7, IFI16, SPP1 and TGFBI was confirmed at protein level in analyzed ovarian cancer patients..
Conclusions:
The expression profiles of the investigated cell lines indicated that new candidate genes are related to the development of resistance to the cytostatic drugs that are used in first- and second-line chemotherapy of ovarian cancer.
Insights
Researchers identified new genes linked to ovarian cancer drug resistance. Microarray analysis revealed altered gene expression in cells resistant to cisplatin, doxorubicin, and paclitaxel, offering potential therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ovarian cancer remains a leading cause of cancer-related mortality in women.
- Acquired resistance to chemotherapy is a major challenge in treating ovarian cancer.
- Identifying novel genes associated with drug resistance is crucial for developing effective therapeutic strategies.
Purpose of the Study:
- To discover novel genes implicated in the development of drug resistance in ovarian cancer.
- To analyze gene expression alterations in response to common chemotherapeutic agents.
Main Methods:
- Gene expression profiling using microarray analysis in ovarian cancer cell lines (W1, A2780) resistant to cisplatin, doxorubicin, topotecan, and paclitaxel.
- Validation of protein expression for selected genes in ovarian cancer patient samples using immunohistochemistry.
Main Results:
- Alterations in the expression of 22 genes were common across cell lines resistant to the same drug.
- Upregulation of 13 genes and downregulation of 9 genes were observed.
- Specific gene expression changes were identified for cisplatin-resistant (e.g., ABCC6, BST2, ERAP2, MCTP1 downregulated) and paclitaxel-resistant (e.g., ABCB1, EPHA7 upregulated; LIPG, MCTP1 downregulated) cell lines.
- Upregulated expression of ABCB1, ABCB4, and IFI16 in doxorubicin-resistant cells.
- Increased expression of ABCG2, HERC5, IFIH1, MYOT, S100A3, SAMD4A, SPP1, and TGFBI in topotecan-resistant cells.
- Protein expression of EPHA7, IFI16, SPP1, and TGFBI was confirmed in patient samples.
Conclusions:
- The study identified novel candidate genes associated with resistance to first- and second-line chemotherapy drugs in ovarian cancer.
- These findings provide a basis for further investigation into the mechanisms of drug resistance and the development of targeted therapies.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
